In prostate cancer patients, the authors observed a longer survival for those individuals carrying the homozygous variant-haplotype, whereby linking their in vitro result on impaired testosterone transport by the variant protein to the observation of enhanced presence of OATP1B3 in prostate cancer cells. Here, SLCO1B3 is linked to prostate cancer.